Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial

Brian H. Kushner, Shakeel Modak, Audrey Mauguen, Ellen M. Basu, Stephen S. Roberts, Nai-Kong V. Cheung · 2025

Read Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial by Brian H. Kushner, Shakeel Modak, Audrey Mauguen, Ellen M. Basu, Stephen S. Roberts, Nai-Kong V. Cheung (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12752410.txt.

Description

BackgroundWith high-risk neuroblastoma, post-induction metastases in bone marrow (BM)/bones confers a poor prognosis but can respond to anti-GD2 antibody, such as naxitamab. We report results of a phase I/II trial.MethodsCycles included GM-CSF and naxitamab infused (30-to-90 min) on days + 1, + 3, + 5. Naxitamab was dose-escalated in the trial’s phase I portion and administered at 9 mg/kg/cycle (i.e.

Catalog record

CREATORBrian H. Kushner, Shakeel Modak, Audrey Mauguen, Ellen M. Basu, Stephen S. Roberts, Nai-Kong V. Cheung
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12752410

Browse the full library · About the Tower of Babel